Indeed, the clinical literature exhibits heterogeneity in design, dosing, duration, and outcome measures, frequent reliance on parent reported scales without uniform blinding, and underpowered samples that hinder strong inference and guideline development (Doherty et al., 2022
J.PellerinL
GHK-Cu + hyaluronic acid : Compatible
doi: 10.1016/S0140-6736(20)32511-3 Summary Keywords chronic liver disorder, metabolic syndrome, non-alcoholic fatty liver disease, oxidative stress, oral glutathione Citation Santacroce G, Gentile A, Soriano S, Novelli A, Lenti MV and Di Sabatino A (2023) Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease